Profile of CGP 61755: A novel and potent HIV-1 protease inhibitor that shows enhanced anti-HIV activity when combined with other antiretroviral agents in vitro

Schweizerische Medizinische Wochenschrift

Volumn 126, Issue 43, 1996, Pages 1849-1851

  Lazdins, J K ^a   Bold, G ^a   Capraro, H G ^a   Cozens, R ^a   Fassler A ^a   Flesch, G ^a   Klimkait, T ^a   Lang, M ^a   Mestan, J ^a   Poncioni, B ^a   Rosel J ^a   Stover, D ^a   Tintelnot Blomley, M ^a   Walker, M R ^a   Woods Cook, K ^a  

^a CIBA GEIGY LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; INDINAVIR; LASINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANIMAL CELL; ANIMAL MODEL; ANTIVIRAL ACTIVITY; BIOAVAILABILITY; CONFERENCE PAPER; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG POTENTIATION; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN;

ANIMALS; ANTI-HIV AGENTS; BLOOD PROTEINS; DOGS; ETHYLENES; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MICE; MICE, INBRED BALB C; PROTEIN BINDING; VIRUS REPLICATION;

EID: 0029839131     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (9)

1. Huff JR: Hiv protease: a novel chemotherapeutic target for AIDS. J Med Chem 1991; 34: 2305-2314.
2. Baker R: FDA approves 3TC and saquinavir. BETA December 1995: 5-9.
3. FDC Reports «The Pink Sheet»: Merck Crixivan launch likely by April following positive advisory committee review; new standard for fast-track reviews by FDA with protease inhibitors. 1996 (March 4): 6.
4. FDC Reports «The Pink Sheet»: Abbot Norvir for HIV reduces death risk 40%, reduces disease progression risk 55% in advanced HIV; FDA approves Ritonavir March 1 in record 72 days. 1996 (March 4): 7-8.
5. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair ED: Crossresistance analysis of human immunodeficiency virus type 1 variants individually selectes for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995; 39: 1704-1710.
6. Massari F, Conant M, Mellors J, Steigbigel R, Mildvan D et al.: A phase II open-label, randomized study in triple combination of indinavir, zidovudine and didanosine versus indinavir alone and zidovudine/didanosine in antiretroviral naive patients. In: Program and abstracts of 3rd Conference on Human Retroviruses and Opportunistic Infections, 1996: Abstract LB7.
7. Alteri E, Bold G, Cozens R, Faessler A, Klimkait T et al.: CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. Antimicrob Agents Chemother 1993; 37: 2087-2092.
8. Lazdins JK, Klimkait T, Woods-Cook K, Walker M, Alteri E et al.: In vitro effect of transforming growth factor-β on progression of HIV-1 infection in primary mononuclear phagocytes. J Immunol 1991; 147: 1201-1207.
9. Sommadossi JP, Schinazi FR, McMillan A, Xie MY, Bryant M: A human serum glycoprotein profoundly affects antiviral activity of the protease inhibitor SC-52151 by decreasing its cellular uptake. In: Program and abstracts of the 2nd National Conference on Human Retroviruses and Related Infections, 1995: Abstract LB4.